A familial mutation renders atrial natriuretic Peptide resistant to proteolytic degradation
- PMID: 19458086
- PMCID: PMC2740543
- DOI: 10.1074/jbc.M109.010777
A familial mutation renders atrial natriuretic Peptide resistant to proteolytic degradation
Abstract
A heterozygous frameshift mutation causing a 12-amino acid extension to the C terminus of atrial natriuretic peptide (ANP) was recently genetically linked to patients with familial atrial fibrillation (Hodgson-Zingman, D. M., Karst, M. L., Zingman, L. V., Heublein, D. M., Darbar, D., Herron, K. J., Ballew, J. D., de Andrade, M., Burnett, J. C., Jr., and Olson, T. M. (2008) N. Engl. J. Med. 359, 158-165). The frameshift product (fsANP), but not wild-type ANP (wtANP), was elevated in the serum of affected patients, but the molecular basis for the elevated peptide concentrations was not determined. Here, we measured the ability of fsANP to interact with natriuretic peptide receptors and to be proteolytically degraded. fsANP and wtANP bound and activated human NPR-A and NPR-C similarly, whereas fsANP had a slightly increased efficacy for human NPR-B. Proteolytic susceptibility was addressed with novel bioassays that measure the time required for kidney membranes or purified neutral endopeptidase to abolish ANP-dependent activation of NPR-A. The half-life of fsANP was markedly greater than that of wtANP in both assays. Additional membrane proteolysis studies indicated that wtANP and fsANP are preferentially degraded by neutral endopeptidase and serine peptidases, respectively. These data indicate that the familial ANP mutation associated with atrial fibrillation has only minor effects on natriuretic peptide receptor interactions but markedly modifies peptide proteolysis.
Figures
![FIGURE 1.](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/2740543/bin/zbc0330982310001.gif)
![FIGURE 2.](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/2740543/bin/zbc0330982310002.gif)
![FIGURE 3.](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/2740543/bin/zbc0330982310003.gif)
![FIGURE 4.](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/2740543/bin/zbc0330982310004.gif)
![FIGURE 5.](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/2740543/bin/zbc0330982310005.gif)
![FIGURE 6.](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/2740543/bin/zbc0330982310006.gif)
![FIGURE 7.](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/2740543/bin/zbc0330982310007.gif)
Similar articles
-
Receptor-specific ligands distinguish natriuretic peptide receptors-A and -C in primate tissues.Mol Cell Biochem. 1998 Jan;178(1-2):317-24. doi: 10.1023/a:1006823732336. Mol Cell Biochem. 1998. PMID: 9546616
-
Differential regulation of natriuretic peptide receptors on ciliary body epithelial cells.Biochem J. 1997 May 15;324 ( Pt 1)(Pt 1):49-55. doi: 10.1042/bj3240049. Biochem J. 1997. PMID: 9164840 Free PMC article.
-
A constitutively "phosphorylated" guanylyl cyclase-linked atrial natriuretic peptide receptor mutant is resistant to desensitization.Mol Biol Cell. 1999 Jun;10(6):1811-20. doi: 10.1091/mbc.10.6.1811. Mol Biol Cell. 1999. PMID: 10359598 Free PMC article.
-
[Molecular biology and pharmacology of natriuretic peptide system].Nihon Rinsho. 1993 Jun;51(6):1548-56. Nihon Rinsho. 1993. PMID: 8100590 Review. Japanese.
-
Natriuretic peptide receptor-C signaling and regulation.Peptides. 2005 Jun;26(6):1044-59. doi: 10.1016/j.peptides.2004.09.023. Epub 2005 Apr 8. Peptides. 2005. PMID: 15911072 Review.
Cited by
-
MANP in Hypertension With Metabolic Syndrome: Proof-of-Concept Study of Natriuretic Peptide-Based Therapy for Cardiometabolic Disease.JACC Basic Transl Sci. 2023 Nov 1;9(1):18-29. doi: 10.1016/j.jacbts.2023.08.011. eCollection 2024 Jan. JACC Basic Transl Sci. 2023. PMID: 38362338 Free PMC article.
-
Novel enhancers of guanylyl cyclase-A activity acting via allosteric modulation.Br J Pharmacol. 2023 Dec;180(24):3254-3270. doi: 10.1111/bph.16203. Epub 2023 Aug 29. Br J Pharmacol. 2023. PMID: 37522273 Free PMC article.
-
Case report: Mutation in NPPA gene as a cause of fibrotic atrial myopathy.Front Cardiovasc Med. 2023 Jun 8;10:1149717. doi: 10.3389/fcvm.2023.1149717. eCollection 2023. Front Cardiovasc Med. 2023. PMID: 37363091 Free PMC article.
-
Taipan Natriuretic Peptides Are Potent and Selective Agonists for the Natriuretic Peptide Receptor A.Molecules. 2023 Mar 29;28(7):3063. doi: 10.3390/molecules28073063. Molecules. 2023. PMID: 37049825 Free PMC article.
-
Role of Cardiac Natriuretic Peptides in Heart Structure and Function.Int J Mol Sci. 2022 Nov 20;23(22):14415. doi: 10.3390/ijms232214415. Int J Mol Sci. 2022. PMID: 36430893 Free PMC article. Review.
References
-
- Potter L. R., Abbey-Hosch S., Dickey D. M. (2006) Endocr. Rev. 27, 47–72 - PubMed
-
- Chinkers M., Garbers D. L., Chang M. S., Lowe D. G., Chin H. M., Goeddel D. V., Schulz S. (1989) Nature 338, 78–83 - PubMed
-
- Suga S., Nakao K., Hosoda K., Mukoyama M., Ogawa Y., Shirakami G., Arai H., Saito Y., Kambayashi Y., Inouye K., Imura H. (1992) Endocrinology 130, 229–239 - PubMed
-
- Lopez M. J., Garbers D. L., Kuhn M. (1997) J. Biol. Chem. 272, 23064–23068 - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous